Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2013 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Reports Third Quarter 2013 Financial Results

Cleared Key Milestones for Resumption of ProHema Phase 2 Clinical Trial Selected Wnt7a Protein Analogs for Advancement into IND-Enabling Activities Extended Breadth of Patent Protection for HSC...
November 06, 2013 16:36 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2013 Financial Results on November 13, 2013

SAN DIEGO, Nov. 6, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan...
October 04, 2013 16:06 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares

SAN DIEGO, Oct. 4, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan...
October 02, 2013 16:10 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at World Muscle Society Congress

SAN DIEGO, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan...
October 01, 2013 08:45 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics, Inc. Announces Pricing of Initial Public Offering

SAN DIEGO, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan...
August 14, 2013 18:43 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Files Registration Statement for Proposed Initial Public Offering

SAN DIEGO, Aug. 14, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, today announced that it has...
April 22, 2013 07:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Presents Preclinical Efficacy Data for WNT7A-Analog Program at Muscular Dystrophy Association 2013 Scientific Conference

SAN DIEGO, April 22, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the...
February 25, 2013 07:29 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Cowen & Co. 33rd Annual Health Care Conference

SAN DIEGO, Feb. 25, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today that Christian...
February 07, 2013 08:30 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at 15th Annual BIO CEO & Investor Conference

SAN DIEGO, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, today announced that Christian...